高级搜索

贝伐单抗联合化疗一线治疗转移性结直肠癌的Meta分析

曲颜丽, 王海峰, 唐勇

曲颜丽, 王海峰, 唐勇. 贝伐单抗联合化疗一线治疗转移性结直肠癌的Meta分析[J]. 肿瘤防治研究, 2014, 41(09): 1002-1008. DOI: 10.3971/j.issn.1000-8578.2014.09.011
引用本文: 曲颜丽, 王海峰, 唐勇. 贝伐单抗联合化疗一线治疗转移性结直肠癌的Meta分析[J]. 肿瘤防治研究, 2014, 41(09): 1002-1008. DOI: 10.3971/j.issn.1000-8578.2014.09.011
shu
QU Yanli, WANG Haifeng, TANG Yong. Bevacizumab Combined with Chemotherapy as First-line Therapy for Metastatic Colorectal Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2014, 41(09): 1002-1008. DOI: 10.3971/j.issn.1000-8578.2014.09.011
Citation: QU Yanli, WANG Haifeng, TANG Yong. Bevacizumab Combined with Chemotherapy as First-line Therapy for Metastatic Colorectal Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2014, 41(09): 1002-1008. DOI: 10.3971/j.issn.1000-8578.2014.09.011
shu

贝伐单抗联合化疗一线治疗转移性结直肠癌的Meta分析

  • 1.830011 乌鲁木齐，新疆医科大学附属肿瘤医院消化内科，2.胸腹放疗科

基金项目: 吴阶平医学基金资助项目（320.6750.13330）
详细信息
    作者简介:

    曲颜丽（1973-），女，硕士，副主任医师，主要从事消化系统肿瘤化学及综合治疗

    通讯作者:

    唐勇，E-mail：ae717ty@163.com

  • 中图分类号: R735.3；R730.5

Bevacizumab Combined with Chemotherapy as First-line Therapy for Metastatic Colorectal Cancer: A Meta-analysis

  • 1.Department of Digestive Tumor, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011,China; 2.Department of Radiotherapy of The Chest and Abdomen

HTML全文

    摘要
  • 摘要: 目的 评价贝伐单抗（bevacizumab,BEV)联合化疗一线治疗转移性结直肠癌（metastatic colorectal cancer, mCRC）的有效性和安全性。方法 通过The Cochrane Library、PubMed、EMBASE 和中国生物医学文献数据库（CBM）、中国期刊全文数据库（CNKI）、维普数据库（VIP）、万方数据库等检索有关BEV联合化疗一线治疗mCRC的随机对照试验（randomized control trial, RCT）；主要研究指标是无进展生存时间（progression free survival, PFS）和总生存时间（overall survival, OS），次要研究指标包括有效率（objective response rate, ORR）和不良反应；采用相对危险度（relative risk, RR）和风险比（hazard ratios, HR）为效应量，各效应量以95%置信区间（95%CI）表示，Stata 11.0统计软件进行Meta分析。结果 共纳入9项RCT，共3 930例mCRC患者，Meta分析结果显示，与单纯化疗相比，贝伐单抗(bevacizumb, BEV)联合化疗可以降低疾病进展风险（HR=0.62, P<0.0001, 95%CI: 0.64~0.74）和疾病死亡风险（HR=0.84, P<0.001,95%CI: 0.73~0.95），提高mCRC 的ORR（RR=0.80, P<0.001,95%CI: 0.60~0.93）。亚组分析显示BEV联合双药方案可降低疾病进展风险（HR=0.68, P<0.001, 95%CI: 0.46~0.89），但并没有降低疾病死亡风险（HR=0.85, P=0.068,95%CI:0.68~1.03）；BEV联合氟尿嘧啶类单药降低疾病进展风险（HR=0.56,P<0.001, 95%CI: 0.47~0.64）和疾病死亡风险（HR=0.83,P<0.001,95%CI:0.68~0.97）。在不良反应方面，B E V 联合化疗没有增加治疗相关死亡率（RR=0.97, P=0.91,95%CI:0.62~1.54）；增加BEV相关不良反应发生率。结论 BEV联合化疗一线治疗能提高mCRC患者PFS、OS和RR。BEV联合不同化疗方案所带来生存获益大小不同。虽然BEV相关不良反应增加，但是可控的。

     

    Abstract: Objective To assess the efficacy and safety of bevacizumab(BEV) combined with chemotherapy as a first-line therapy for metastatic colorectal cancer(mCRC). Methods A wide search of randomized clinical trials using BEV combined with chemotherapy as a first-line therapy for mCRC patients was performed in the Cochrane Library，PubMed，EmBase and CBM，CNKI，VIP，WanFang databases. Primary outcomes were overall survival (OS) and progression-free survival (PFS). Secondary outcomes were objective response rate (ORR) and toxicity. Relative risk (RR) and hazard ratios (HR) were expressed by 95% confidence intervals (95%CI). The software Stata 11.0 was used for meta-analysis. Results We involved 9 RCT trials, totally 3930 patients. Meta analysis indicated that compared with chemotherapy alone, BEV combined with chemotherapy could decrease the risk of progressive disease（HR=0.62, P<0.0001, 95%CI: 0.64-0.74）and the risk of disease death（HR=0.84, P<0.001, 95%CI: 0.73-0.95）, and could increase the ORR of mCRC patients（RR=0.80, P<0.001, 95%CI: 0.60-0.93）. Subgroup analysis indicated that the combination of BEV and double therapy could decrease the risk of progressive disease（HR=0.68, P<0.001, 95%CI: 0.46-0.89），but no decrease in the risk of disease death(HR=0.85, P=0.068, 95%CI: 0.68-1.03). The combination of BEV and monotherapy could decrease the risk of progressive disease(HR=0.56, P<0.001, 95%CI: 0.47-0.64) and the risk of disease death(HR=0.83, P<0.001, 95%CI: 0.68-0.97). Regarding the toxicity, BEV combined with chemotherapy didn't increase the treatment-related mortality(RR=0.97, P=0.91, 95%CI: 0.62-1.54), but increased the rates of BEV-associated adverse effects. Conclusion BEV combined with chemotherapy as a first-line treatment could increase the PFS,OS and ORR of mCRC patients. The benefit was dissimilar between BEV with monotherapy and BEV with double therapy. Although the BEVassociated adverse effect was increased, they could be controlled.

     

    • HTML全文
    • 参考文献(16)
  • [1] Hurwitz H, Fehrenbacher L, Novotny W,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J].N Engl J Med,2004,350(23):2335-42.
    [2] Alessandro Passardi, Emanuela Scarpi, Luigi Cavanna, et al. Effectiveness of bevacizumab added to gold standard chemotherapy in metastatic colorectal cancer (mCRC): Final results from the Itaca randomized clinical trial[J]. J Clin Oncol, 20 13 ASCO Annual Meeting Abstracts,3517.
    [3] Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase Ⅲ study [J]. J Clin Oncol,2008,26(12):2013-9.
    [4] Stathopoulos GP, Batziou C, Trafalis D, et al. Treatment of colorectal cancer with and without bevacizumab: a phase Ⅲ study[J].Oncology,2010,78(5-6):376-81.
    [5] Guan ZZ, Xu JM, Luo RC, et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase Ⅲ ARTIST trial[J]. Chin J Cancer, 2011,30(10):682-9.
    [6] Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase Ⅱ, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2003,21(1):60-5.
    [7] Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase Ⅱ trial [J] J Clin Oncol, 2005,23(16):3697-705.
    [8] Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase Ⅲ MAX Study[J].J Clin Oncol, 20 10,28(19):3191-8.
    [9] Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial[J].Lancet Oncol,2013,14 (11) :1077-85.
    [10] Kozloff M, Yood MU, Berlin J, et al.Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study[J]. Oncologist, 20 09,14(9):862-70.
    [11] Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study[J].Ann Oncol,2009,20(11):1842-7.
    [12] Hurwitz HI, Tebbutt NC, Kabbinavar F, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials[J].Oncologist, 20 13,18(9):1004-12.
    [13] Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups[J].BMC Cancer, 2012,12:89.
    [14] Loupakis F, Bria E, Vaccaro V, et al. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials[J].J Exp Clin Cancer Res,2010, 29:58.
    [15] Strickler JH, Hurwitz HI. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer[J].Oncologist, 20 12,17(4):513-24.
    [16] Dai F, Shu L, Bian Y, et al. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials[J].Clin Drug Investig,2013,33(11): 77 9-88.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1328
  • HTML全文浏览量:  348
  • PDF下载量:  389
  • 被引次数: 0
出版历程
  • 刊出日期:  2014-09-24

目录

摘要
HTML全文
    参考文献(16)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：11739917 今日访问：7650

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭